Literature DB >> 26552950

CHAARTED/GETUG 12--docetaxel in non-castrate prostate cancers.

Min Yuen Teo1, Howard I Scher1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26552950     DOI： 10.1038/nrclinonc.2015.192

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

Review 1.  High-risk prostate cancer-classification and therapy.

Authors:  Albert J Chang; Karen A Autio; Mack Roach; Howard I Scher
Journal:  Nat Rev Clin Oncol       Date:  2014-05-20       Impact factor: 66.675

2.  Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

Authors:  Karim Fizazi; Laura Faivre; François Lesaunier; Remy Delva; Gwenaëlle Gravis; Frédéric Rolland; Frank Priou; Jean-Marc Ferrero; Nadine Houede; Loïc Mourey; Christine Theodore; Ivan Krakowski; Jean-François Berdah; Marjorie Baciuchka; Brigitte Laguerre; Aude Fléchon; Alain Ravaud; Isabelle Cojean-Zelek; Stéphane Oudard; Jean-Luc Labourey; Paule Chinet-Charrot; Eric Legouffe; Jean-Léon Lagrange; Claude Linassier; Gaël Deplanque; Philippe Beuzeboc; Jean-Louis Davin; Anne-Laure Martin; Muriel Habibian; Agnès Laplanche; Stéphane Culine
Journal:  Lancet Oncol       Date:  2015-05-28       Impact factor: 41.316

3.  The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.

Authors:  Emmanuel S Antonarakis; Zhaoyong Feng; Bruce J Trock; Elizabeth B Humphreys; Michael A Carducci; Alan W Partin; Patrick C Walsh; Mario A Eisenberger
Journal:  BJU Int       Date:  2011-07-20       Impact factor: 5.588

Review 4.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Authors:  Axel Heidenreich; Patrick J Bastian; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Theodor van der Kwast; Malcolm Mason; Vsevolod Matveev; Thomas Wiegel; Filiberto Zattoni; Nicolas Mottet
Journal:  Eur Urol       Date:  2013-11-12       Impact factor: 20.096

5.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

6.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346).

Authors:  Catherine M Tangen; Maha H A Hussain; Celestia S Higano; Mario A Eisenberger; Eric J Small; George Wilding; Bryan J Donnelly; Paul F Schelhammer; E David Crawford; Nicholas J Vogelzang; Isaac J Powell; Ian M Thompson
Journal:  J Urol       Date:  2012-08-22       Impact factor: 7.450

8.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Authors:  Christopher J Sweeney; Yu-Hui Chen; Michael Carducci; Glenn Liu; David F Jarrard; Mario Eisenberger; Yu-Ning Wong; Noah Hahn; Manish Kohli; Matthew M Cooney; Robert Dreicer; Nicholas J Vogelzang; Joel Picus; Daniel Shevrin; Maha Hussain; Jorge A Garcia; Robert S DiPaola
Journal:  N Engl J Med       Date:  2015-08-05       Impact factor: 91.245

9.  Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

Authors:  Gwenaelle Gravis; Karim Fizazi; Florence Joly; Stéphane Oudard; Franck Priou; Benjamin Esterni; Igor Latorzeff; Remy Delva; Ivan Krakowski; Brigitte Laguerre; Fréderic Rolland; Christine Théodore; Gael Deplanque; Jean Marc Ferrero; Damien Pouessel; Loïc Mourey; Philippe Beuzeboc; Sylvie Zanetta; Muriel Habibian; Jean François Berdah; Jerome Dauba; Marjorie Baciuchka; Christian Platini; Claude Linassier; Jean Luc Labourey; Jean Pascal Machiels; Claude El Kouri; Alain Ravaud; Etienne Suc; Jean Christophe Eymard; Ali Hasbini; Guilhem Bousquet; Michel Soulie
Journal:  Lancet Oncol       Date:  2013-01-08       Impact factor: 41.316
  9 in total
  1 in total

Review 1.  Androgen deprivation and immunotherapy for the treatment of prostate cancer.

Authors:  Melissa Gamat; Douglas G McNeel
Journal:  Endocr Relat Cancer       Date:  2017-08-16       Impact factor: 5.678
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.